#United States #Boston #Precision Medicine #SOPHiA GENETICS #AI-Driven Healthcare

SOPHiA GENETICS Reports Impressive Q2 2026 Results

On August 4, 2026, SOPHiA GENETICS, a leading company in AI-driven precision medicine, shared its financial performance for the second quarter ending June 30, 2026, marking a remarkable growth trajectory.

Financial Highlights

SOPHiA GENETICS reported a revenue of $23.3 million, an impressive increase of 27% compared to the same period last year. This robust performance showcases the company's resilience and effectiveness in a rapidly evolving market.

The gross margin also witnessed a healthy standing at 64.6%, while the adjusted gross margin climbed to 72.1%. It's worth noting that the net loss remained constant at $22.4 million, but the adjusted EBITDA loss showed signs of improvement, decreasing by 27% year-over-year to $8.8 million.

Further solidifying its optimistic outlook, SOPHiA GENETICS raised its revenue guidance for 2026 to a projected range of $94 million to $96 million, signaling a year-over-year growth of 22% to 24%. Previously, the guidance was set lower, indicating the company's accelerating operational performance and market demand.

CEO's Insight

Ross Muken, the Chief Executive Officer of SOPHiA GENETICS, expressed enthusiasm over the results, asserting, “We delivered an outstanding second quarter, where our revenue surged by 27% year-over-year and adjusted EBITDA losses remarkably improved.” This statement reflects the company's strategic focus on enhancing its operational efficiency and expanding its customer base.

Muken highlighted that the strong revenue growth was primarily driven by a 60% volume increase in the U.S. market and a 70% rise in Liquid Biopsy services. He noted that the future seems promising, especially with significant collaborations in the BioPharma sector, including partnerships with AstraZeneca to implement companion diagnostic programs for oncology.

Business Expansion and Customer Growth

Existing Customer Engagement

In Q2 2026, SOPHiA GENETICS conducted a record 115,000 analyses through its SOPHiA DDM™ platform, achieving a 22% year-over-year growth in analysis volume. The company’s retention metrics also reflected success, as their Net Dollar Retention improved to 117%, attributed to a growing base of 542 core genomics customers.

New Client Acquisition

On the front of acquiring new customers, SOPHiA GENETICS signed 24 new core genomic customers in Q2, positioning itself strongly for upcoming revenue streams. The partnerships included prestigious health institutions like the Nova Scotia Health Authority and Brazil's DB Diagnósticos, showcasing the company's expanding reach across the globe.

U.S. Market Dynamics

SOPHiA GENETICS discerned a 64% revenue growth in the U.S. market along with innovations in its service offerings. Notably, they initiated a strategic collaboration with the Children’s Hospital of Philadelphia to develop a next-generation liquid biopsy application tailored for pediatric oncology, which underscores their commitment to specialized healthcare solutions.

Innovation and Development

SOPHiA GENETICS is not only focused on current markets but is also scaling its growth through updated applications. The Liquid Biopsy application saw an 80% revenue increase, with a total of 80 customers from over 30 countries adopting the technology. The newly signed customers included reputable institutions like AZ Delta in Belgium and Policlinico Riuniti Hospital in Italy, exemplifying the extensive demand for their offerings.

Furthermore, the signing of a Memorandum of Understanding with the Memorial Sloan Kettering Cancer Center to create a joint venture amplifies their commitment to fostering innovation in precision oncology.

Financial Outlook

Looking ahead, SOPHiA GENETICS anticipates a full year revenue between $94 million and $96 million for 2026. They also expect an adjusted EBITDA loss between $29 million and $32 million, significantly lower than the previous year’s losses.

In conclusion, SOPHiA GENETICS is well-positioned to maintain its momentum through continued strategic expansions and innovative healthcare solutions. Their performance in Q2 2026 not only highlights their operational strength but also hints at a promising future trajectory in the realm of precision medicine, further supporting the integration of AI in healthcare.